Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gleave

Showing results (741-750 of 839) with videos related to

Pageof 84
Sort By:
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
EMBO Reports|November 1, 2019
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasisAmal M El-Naggar, Syam Prakash Somasekharan, Yemin Wang, et al.
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Pathology|February 20, 2015
Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour developmentQian Wang, Rae-Anne Hardie, Andrew J Hoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate CancerJames A Eastham, Glenn Heller, Susan Halabi, et al.
Cancer Research|May 14, 2021
SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate CancerRafael S Martinez, Mark J Salji, Linda Rushworth, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2025
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancerBetul Ersoy-Fazlioglu, Shreyas Lingadahalli, Umut Berkay Altintas, et al.
European Urology Oncology|September 25, 2025
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional CohortsAshwini Uchil, Louis Lacombe, Hélène Hovington, et al.
Pageof 84

Showing results (741-750 of 839) with videos related to

Sort By:
Pageof 84
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
EMBO Reports|November 1, 2019
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasisAmal M El-Naggar, Syam Prakash Somasekharan, Yemin Wang, et al.
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Pathology|February 20, 2015
Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour developmentQian Wang, Rae-Anne Hardie, Andrew J Hoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate CancerJames A Eastham, Glenn Heller, Susan Halabi, et al.
Cancer Research|May 14, 2021
SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate CancerRafael S Martinez, Mark J Salji, Linda Rushworth, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2025
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancerBetul Ersoy-Fazlioglu, Shreyas Lingadahalli, Umut Berkay Altintas, et al.
European Urology Oncology|September 25, 2025
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional CohortsAshwini Uchil, Louis Lacombe, Hélène Hovington, et al.
Pageof 84